Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
Bangladesh’s deadliest measles outbreak is showing no signs of abating. Since March, the highly infectious disease has claimed nearly 600 children, while suspected cases have crossed 72,000.
What is more worrying is that there are no signs of a slowdown despite nationwide vaccination efforts, and experts believe infections could surge further following increased transmission during the Eid Al-Adha homecoming period.
“Over the weekend, Bangladesh documented more than 1,300 suspected measles cases and two deaths, pushing the country’s tally to nearly 71,000 infections and 585 fatalities since the outbreak began in mid-March,” according to the Bangladeshi Directorate General of Health Services (DGHS).
As many as 56,886 suspected measles patients have been hospitalized in Bangladesh since March 15, of whom 52,841 have recovered, according to the DGHS, United News of Bangladesh reported.
“There is no sign of a downtrend in measles infection rate across the country,” Dr. Ariful Bashar from Mohakhali Contagious Disease Hospital told Arab News.
“Measles is a highly contagious disease, even six times more than COVID-19. Unless 95 percent immunity is achieved through vaccination, there will be no downtrend in the infection rate,” he added.
Also read: Measles Again On The Rise Globally: Is India At Risk?
Notably, millions of Bangladeshis travelled to their hometowns last week to celebrate Eid Al-Adha.
Bashar said that “as health protocols were not maintained properly”, the country is likely to “witness a future increase in the infection rate”.
The expert noted that Bangladesh also lacks facilities for efficient contact tracing of measles patients, which could further increase the spread of what he described as “the most contagious disease in the world”.
Since March, hospitals across the country have been overwhelmed as they struggle to isolate and treat hundreds of children admitted every day.
Dr. Mirza Ziaul Islam, director of the Bangladesh Shishu Hospital and Institute, told Arab News that “during the Eid travel period, it was not possible to keep infected patients isolated”, increasing the risk of further transmission.
Also read: India Concerned Over Measles Outbreak, Action Underway: Dr N K Arora| Exclusive
Four out of five measles patients are younger than five years, according to The New York Times. The vast majority of deaths have also occurred in this age group, which is highly vulnerable to the airborne virus.
According to the United Nations International Children's Emergency Fund (UNICEF), Bangladesh had largely contained measles outbreaks since the 1990s through vaccination campaigns. However, immunization efforts were disrupted in 2024 after student-led protests overthrew the government.
The interim administration that governed Bangladesh until elections in late February did not conduct a supplementary mass vaccination campaign as recommended.
Last week, UNICEF said it had repeatedly warned the country’s interim government, led by Muhammad Yunus, through written communications and meetings with Health Ministry officials about vaccine shortages that could trigger a major health crisis, local media reported.
In April, Bangladesh’s new government launched an emergency campaign to vaccinate 20 million children.
Although the campaign has reportedly achieved 110 percent of its target and remains ongoing, experts note that only one of the two doses required for strong and durable immunity has been administered so far.
In addition, it takes four to six weeks for immunity to develop after vaccination.
The outbreak began in January in Rohingya refugee camps near the Myanmar border and quickly spread nationwide. It has now reached 58 of Bangladesh’s 64 districts, causing more than 21,000 hospitalisations.
In an April 23 update, the World Health Organization (WHO) warned of a “considerable risk” of spread to Myanmar, where civil strife has disrupted immunisation efforts, and to India, which remains vulnerable. WHO described the outbreak as “a reversal from Bangladesh’s previous progress towards measles elimination.”
Credit: @EmbaCubaUS/X
Scientists in Cuba have developed a novel vaccine against lung cancer that has shown the potential to improve survival rates among people living with the disease.
The vaccine, chemically known as racotumomab, has been developed in collaboration with scientists from Argentina. Vaxira has been approved in Cuba and Argentina for advanced non-small cell lung cancer (NSCLC).
It helps the immune system recognize and destroy lung cancer cells.
According to the Cuban Embassy in the US, the vaccine "works by mimicking a molecule found on cancer cells but almost entirely absent in healthy human tissue". It also targets tumors with remarkable precision and has very few side effects.
While advanced NSCLC has limited curative options and poor survival rates, clinical trials of Vaxira showed a significant improvement in survival.
Notably, "one-year survival among patients receiving the vaccine nearly doubled compared with the control group," the post said.
"Real-world data shows median survival of up to 24.5 months in maintenance therapy," it added.
Improved Survival And Minimal Side Effects
Importantly, the vaccine has demonstrated minimal side effects and is considered suitable for long-term use.
The embassy described the vaccine as affordable and accessible compared with many immunotherapies.
In 2025, Vaxira also received Cuba's National Technological Innovation Award.
The commercial rollout of Vaxira is being facilitated by the international public-private consortium ReComBio, linking Havana's Center of Molecular Immunology (CIM) with Argentina's Elea Laboratories.
Also read: Potential 'Functional Cure' For Hepatitis B: Trial Give Hope To Millions
Lung Cancer is one of the most common and serious types of cancer. It is also the leading cause of cancer-related deaths worldwide, with approximately 2.5 million new cases and 1.8 million deaths reported in 2022.
According to the American Cancer Society, lung cancer mainly occurs in older people. Most people diagnosed with lung cancer are 65 or older; a very small number of people diagnosed are younger than 45.
The average age of people when diagnosed is about 70.
It is also the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.
The two main types of lung cancers are:
Non-small-cell lung cancer (NSCLC): This is the most common form, making up about 80–85% of all cases. NSCLC includes three subtypes:
Small-cell lung cancer (SCLC): Less common than NSCLC, this type tends to grow and spread more quickly.
Lung cancer symptoms can mimic less serious conditions, which is why they’re often dismissed or misdiagnosed. If you experience the following symptoms persistently, don’t ignore them—regardless of your age or smoking history:
Credit: AI generated image
The International Space Station is conducting a very important study as Expedition 74 astronauts are researching how to manufacture large quantities of stem cells for treatment purposes on Earth. Research previously mostly worked on hardware to produce a large amount of stem cells, but now the InSPA-StemCellEX-H2 is trying to produce the cells for medical purposes.
This endeavor will rely on the process called “expansion”, which will use the stem cells from the human body and divide them. Though this is already possible on earth, the quality of created stem cells is far poorer than those from the human body, as it cannot create new cells in the blood, but the ones created in space will solve this problem, which will be crucial in the treatment of leukemia, as they need stem cells in the blood system post-chemotherapy.
Dr. Tobias Niederwieser, assistant research professor at BioServe Space Technologies within the University of Colorado Boulder, says, “The microgravity environment in space is much more suitable for keeping the stem cells in their high-quality state during expansion.” He added, “The result is really to benefit patients in hospitals here on Earth.”
Read Also: Pancreatic Cancer: What Is The Role Of Keratin 17 In Driving The Feared Disease?
© 2024 Bennett, Coleman & Company Limited